Safety and tolerability of zoster vaccine in adults ≥60 years old

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1130-1136

  Murray, Alexander V ^a   Reisinger, Keith S ^b   Kerzner, Boris ^c   Stek, Jon E ^d   Sausser, Timothy A ^d   Xu, Jin ^d   Wang, William W ^d   Chan, Ivan S F ^d   Annunziato, Paula W ^d   Parrino, Janie ^d  

^a PharmQuest   (United States)

^b Primary Physicians Research   (United States)

^c Health Trends Research   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Clinical study; Herpes zoster; Safety; Tolerability; Zoster vaccine

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; BREAST DISEASE; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEART ATRIUM FIBRILLATION; HEPATOBILIARY DISEASE; HERPES ZOSTER; HUMAN; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; INTOXICATION; ISCHIALGIA; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PROCEDURAL SITE REACTION; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; THORAX DISEASE; URINARY TRACT DISEASE; UVEITIS; VACCINATION REACTION; VASCULAR DISEASE;

EID: 81855227712     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17982     Document Type: Article

References (18)

1. Creed R, Satyaprakash A, Tyring SK. Varicella Zoster Virus. In: Tyring SK, Yen Moore A, Lupi O, (Eds). Mucocutaneous Manifestations of Viral Diseases, London: Informa Healthcare 2010; 2:98-122.
2. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on qualityof- life. BMC Med 2010; 8:37; PMID:20565946; DOI:10.1186/1741-7015-8-37.
3. Zostavax (zoster vaccine, live) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. 2009. Available at: http://www.merck.com/product/usa/ pi-circulars/z/zostavax/zostavax-pi2.pdf. Accessed 31-May-2011.
4. Centers for Disease Control and Prevention. Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2008; 57:1- 5; PMID:18185492.
5. National Health & Medical Research Council. The Australian immunisation handbook. Williams A, Ed. Canberra: Australian Government Publishing Service 2008.
6. EMEA Committee for Medicinal Products for Human Use. Product information for ZOSTAVAXTM. http:// www.emea.europa.eu/humandocs/PDFs/EPAR/ zostavax/H-674-PI-en.pdf. Accessed 27-Mar-2009.
7. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; DOI:10.1056/NEJMoa051016.
8. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Safety of Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial. Ann Intern Med 2010; 152:545-54; PMID:20439572.
9. Levin MJ, Oxman MN, Bobrove AM, Hayden FG, Hayward AR, Irwin M, et al. Dose ranging safety and immunogenicity study of live attenuated Varicella- Zoster virus (VZV) vaccine (Oka/Merck) administered to adults 60 years of age or older: GER-3. South Med J 2005; 98:55; DOI:10.1097/00007611-200510001- 00151.
10. Schmader KE, Bobrove AM, Levin MJ, Oxman M, Tucker R, Reisinger K, et al. Immunogenicity & Safety of Varicella-Zoster Virus (VZV) Vaccine Administered to Older Adults With or Without Diabetes Mellitus (DM) or Chronic Obstructive Pulmonary Disease (COPD). In: Program and abstracts of the Annual Scientific Meeting of the American Geriatrics Society; May 5, 2006; Chicago IL. Abstract #227638.
11. Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al. Safety and immunogenicity of a high-potency zoster vaccine in varicellazoster virus seronegative and low-seropositive healthy adults. Vaccine 2007; 25:2139-44; PMID:17250932; DOI:10.1016/j.vaccine.2006.11.011.
12. + T-cell γIFN Production and Safety of a Live Attenuated Oka/Merck Zoster Vaccine in Healthy Adults ≥60 Years of Age. In: Program and abstracts of the 44th Annual Meeting if the Infectious Diseases Society of America; October 12-15 2006; Toronto, Canada. Abstract #857.
13. Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine 2007; 25:1877-83; PMID:17227688; DOI:10.1016/j.vaccine. 2006.10.027.
14. Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al. A Double- Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of ZOSTAVAX® . [Comment in: Clin Vaccine Immunol 2009; 16:1381]. Clin Vaccine Immunol 2008; 15:314-9; PMID:18077611; DOI:10.1128/CVI.00310-07.
15. Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55:1499- 507; PMID:17908055; DOI:10.1111/j.1532- 5415.2007.01397.x.
16. MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, et al. Concomitant Administration of Zoster and Pneumococcal Vaccines in Adults ≥60 Years Old. Hum Vaccin 2010; 6:894- 902; PMID:20980796; DOI:10.4161/hv.6.11.12852.
17. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, et al. Safety, Tolerability and Immunogenicity of Zoster Vaccine in Subjects With a History of Herpes Zoster (HZ). Vaccine 2010; 28:4204-9; PMID:20416263; DOI:10.1016/j. vaccine.2010.04.003.
18. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26; PMID:4023479; DOI:10.1002/sim.4780040211.